Phase I / II Study Of ColoAd1 Intraperitoneally in Ovarian Cancer Patients
Patients With Recurrent, Platinum-resistant Ovarian Cancer.
Conditions: official terms
Ovarian Neoplasms
Study Type
Study Phase
Phase 1/Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: ColoAd1
Type: Biological
Overall Status
This study is a phase I/II open label clinical study in patients with platinum-resistant epithelial ovarian cancer. The Phase I part of the study will determine the dose of ColoAd1 to be recommended for further studies and will examine primarily the safety and tolerability but also the pharmacokinetics of administering ColoAd1 intraperitoneally. Once the dose of IP ColoAd1 to be used in combination with IV weekly paclitaxel has been determined, the phase II stage will begin as an open label dose expansion of that regimen. The phase II stage aims to determine whether intraperitoneal ColoAd1 has a risk benefit profile that supports further investigation in the treatment of patients with platinum-resistant epithelial ovarian Cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

1. Able and willing to provide written informed consent and to comply with the study protocol

2. Age ≥ 18 years

3. Histologically confirmed non-resectable ovarian, fallopian tube or primary peritoneal cancer

4. Confirmed relapsed within the platinum-resistant time frame.

- Platinum-resistance is defined as progression within 6 months of receiving prior platinum-containing chemotherapy, with progression identified either by CT scanning (RECIST v1.1) or symptomatic CA125 progression (GCIG CA-125 criteria).

- The treatment immediately prior to study entry need not be platinum-based.

5. Measurable disease (by RECIST v1.1).

6. Able to undergo intraperitoneal injection and comply with study procedures in the Investigator's opinion

7. Recovered to at least Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancy

8. ECOG Performance Status Score of 0 - 1

9. Adequate renal function

- Creatinine ≤ 1.8 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 mL/min, or measured creatinine clearance ≥ 45 mL/min,

- Absence of clinically significant haematuria on urinalysis: dipstick <2+

- Absence of clinically significant proteinuria on urinalysis: dipstick < 2+.

10. Adequate hepatic function

- serum bilirubin <1.5 x ULN

- AST and ALT ≤ 3 x ULN

11. Adequate bone marrow function:

- ANC ≥ 1.5 x 109/L,

- platelets ≥ 100 x 109/L,

- haemoglobin ≥ 90 g/L

12. Adequate coagulation tests: INR ≤ 1.5 x ULN;

13. Access to archival tumour samples

14. For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment;

15. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period and for at least 3 months after the last dose of study drug;

16. For patients in the Phase II part of the study participating in the exploratory assessment of tumour samples:

- Ovarian Disease amenable to percutaneous image-guided biopsy.

Exclusion Criteria:

1. Tumours of malignant mixed mesodermal (MMMT) or mucinous subtypes, or non-epithelial ovarian cancers (e.g. Brenner tumours, Sex-cord tumours).

2. For Phases Ib and II only: Prior treatment with weekly paclitaxel monotherapy. Prior treatments with other schedules of paclitaxel or combination chemotherapy including weekly paclitaxel are accepted.

3. Unresolved bowel obstruction;

4. Extensive intra-abdominal adhesions and / or tumoural involvement of the small bowel

5. Pregnant or lactating (nursing) women;

6. Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks);

7. Splenectomy;

8. Prior allogeneic or autologous bone marrow or organ transplantation;

9. Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection;

10. Active viral disease, positive serology for HIV, hepatitis B or hepatitis C;

11. Use of the following anti-viral agents:

- ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1;

- or PEG-IFN (within 14 days prior to day 1);

12. Administration of an investigational drug within 28 days or within 5 half-lives of first dose of ColoAd1, whichever is longer.

13. Administration of a systemic cancer therapy within 3 weeks of the first administration of Coload1

14. Major surgery within 3 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1;

15. Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ);

16. Known CNS metastasis;

17. Inflammatory diseases of the bowel;

18. Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease.

19. Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug;

20. Known allergy to treatment medication or its excipients;

21. Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
The Royal Surrey County Hospital
Guildford, Surrey, United Kingdom
Status: Recruiting
Contact: Agnieszka Michael, MD
Beatson Institute
Glasgow, United Kingdom
Status: Recruiting
Contact: Iain McNeish, MD - 0141 330 3968 -
St James's University Hospital
Leeds, United Kingdom
Status: Recruiting
Contact: Chris Twelves, MD
The Christie Hospital
Manchester, United Kingdom
Status: Recruiting
Contact: Gordon Jayson, MD
Start Date
January 2014
Completion Date
December 2016
PsiOxus Therapeutics Ltd
PsiOxus Therapeutics Ltd
Record processing date processed this data on July 28, 2015 page